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A large proportion of end‑stage renal disease (ESRD) patients under long‑term haemodialysis, 
have persistent anaemia and require high doses of recombinant human erythropoietin (rhEPO). 
However, the underlying mechanisms of renal anaemia have not been fully elucidated in these 
patients. In this study, we will be focusing on anaemia and plasma proteins in ESRD patients on high‑
flux haemodialysis (HF) and on‑line haemodiafiltration (HDF), to investigate using two proteomic 
approaches if patients undergoing these treatments develop differences in their plasma protein 
composition and how this could be related to their anaemia. The demographic and biochemical data 
revealed that HDF patients had lower anaemia and much lower rhEPO requirements than HF patients. 
Regarding their plasma proteomes, HDF patients had increased levels of a protein highly similar to 
serotransferrin, trypsin‑1 and immunoglobulin heavy constant chain alpha‑1, and lower levels of 
alpha‑1 antitrypsin, transthyretin, apolipoproteins E and C‑III, and haptoglobin‑related protein. Lower 
transthyretin levels in HDF patients were further confirmed by transthyretin‑peptide quantification 
and western blot detection. Since ESRD patients have increased transthyretin, a protein that can 
aggregate and inhibit transferrin endocytosis and erythropoiesis, our finding that HDF patients have 
lower transthyretin and lower anaemia suggests that the decrease in transthyretin plasma levels 
would allow an increase in transferrin endocytosis, contributing to erythropoiesis. Thus, transthyretin 
could be a critical actor for anaemia in ESRD patients and a novel player for haemodialysis adequacy.
There are an increased number of end-stage renal disease (ESRD) patients requiring renal replacement  treatment1. 
Haemodialysis is the main replacement treatment for patients with ESRD. It is the resource for patients waiting 
for a kidney transplant, or patients who are not candidates for transplantation.
In haemodialysis systems, new membranes have been developed with the aim of achieving a better renal 
substitute. High-flux membranes, with larger pore size, allowing a greater middle-sized molecule clearance, 
and better biocompatibility improve clinical  outcomes2. The latest development is on-line haemodiafiltration 
that combines diffusion with elevated convection, as well as preparing the substitution fluid from water and 
open
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 concentrate3. However, at present, whether high-flux or on-line haemodiafiltration is more appropriate remains 
under  discussion4.
Renal anaemia appears in most chronic renal disease patients independently of the etiology of their kidney 
 disease5. It has been described that anaemia persists in 50% ESRD patients under long-term haemodialysis, 
despite appropriate recombinant human erythropoietin (rhEPO) administration and iron supplementation. 
Anaemia has a negative effect on quality of life, and it is associated with increased cardiovascular disease and 
decreased life  expectancy5. However, the underlying mechanisms of renal anaemia have not yet been elucidated 
in dialyzed patients and renal anaemia does not completely respond to rhEPO, suggesting that there are more 
elements at stake.
Over the last decade, plasma proteins from patients undergoing haemodialysis have attracted greater atten-
tion. It has been reported that haemodialysis patient’s plasma proteomes are different compared with healthy 
human  subjects6. Proteomic techniques enable the identification and comparison of serum proteins from patients 
in different haemodialysis therapies in a non-invasive way. Serum protein levels of patients after low- and high-
flux haemodialysis have recently been studied, and major differences have been  found7. A proteomic approach 
enables the study of the protein removal of haemodialysis membranes, assessing their ability to remove toxic 
metabolites as well as the undesired loss of vital  proteins8.
In this study, we compare patients on high-flux haemodialysis treatment (HF) against patients on on-line 
haemodiafiltration (HDF), focusing on the proteomic study of anaemia in both groups of patients since this is 
an area of interest which remains to elucidate. We hypothesised that patients undergoing these therapies might 
develop differences in their plasma protein composition and that these might, in turn, affect the proteomic 
composition of their blood and have an impact on their anaemia. To address this issue, data from HF and HDF 
patients were collected from the database, and their plasma samples were compared by fluorescence difference in 
gel electrophoresis (DIGE). Differentially detected proteins were quantified and then identified by matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). In addition, a quantitative 
proteomics analysis based on liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS) 
was performed in HDF and HF patients’ plasma samples.
Results
Demographic and biochemical data. The demographic and biochemical data and the treatment pre-
scription details of the participating patients are summarized in Table 1. Patients were similar in age, gender, 
anthropometrical indices (height, weight and body mass index), blood pressure, albumin, creatinine, electrolytes, 
fasting blood sugar, lipid profile, liver function parameters, calcium-phosphate metabolism and iron reserve. 
The groups did not differ in dialysis vintage; and the Charlson Comorbidity Index and pre-dialytic urea values 
were similar. Differences between the HF and HDF patients’ groups were found for the Kt/V  value9, having HDF 
patients a higher Kt/V (Table 1). Given that none of the patients had a residual renal function, the Kt/V and 
the Total Kt/V values within each group were the same. As expected, blood flow rate and Kt were significantly 
higher in HDF patients (p = 0.0001 and p = 0.0027, respectively), since on-line haemodiafiltration works with 
greater convection volumes. HDF patients did also have lower post-dialytic urea levels, however, this difference 
was not significant (p = 0.1559) (Table 1). Interestingly, HF patients had hyperuricemia (8.73 ± 0.47 mg/dL uric 
acid, > 6.8 mg/dL), whereas HDF patients had lower uric acid levels (6.78 ± 0.37 mg/dL), being this difference 
significant (p = 0.0075) (Table 1). Regarding anaemia control, the ferritin level was similar in both groups, and 
all HF patients required rhEPO (mean, 9,200 U/week). Conversely, anaemia control in HDF patients was much 
better, since only three patients required rhEPO and in lower doses (mean, 5,000 U/week). Hence, the difference 
in the number of patients requiring rhEPO was very significant (p = 0.0031) (Table 1). Despite this treatment, the 
haemoglobin and haematocrit of HF patients were lower than those of HDF patients (Table 1).
Differential protein detection in plasma samples of HF and HDF patients. Differential protein 
detection of plasma samples of HF compared with HDF patients was performed by fluorescence DIGE assay. 
Individual and pools of HF and HDF patients’ plasma samples were depleted of albumin and IgG and labelled 
with fluorescent Cy3 and Cy5 dyes (Fig. 1A). Individual samples were analyzed combining each time a labelled 
sample from one HF patient with a corresponding labelled sample from another HDF, resulting in nine different 
biological replicates (Supplemental Figure S2). All detected proteins in HF and HDF patients were then quanti-
fied for differential protein detection. The results showed that HF samples had significantly higher levels than 
HDF samples for three proteins, named as a, b and c (2.1-, 1.6- and 1.9-fold, respectively) (Fig. 1B). To identify 
these differentially detected proteins pools of both HF and HDF samples were Cy-labelled and combined into 
SDS-PAGE and gels were stained with Coomassie blue (Fig. 1C) for subsequent protein digestion and identifica-
tion by MALDI-TOF MS. The results of MS identification of a to c proteins are shown in Table 2.
In order to confirm the identification of the proteins a to c, unlabelled samples depleted of albumin and 
IgG from each pool of HF and HDF patients’ plasma were run into SDS-PAGE and the gels were stained with 
Coomassie blue (Fig. 2). The stained gels allowed the detection of 24 different proteins (bands) (Fig. 2), which 
were then excised from the gel for later protein digestion and identification by MALDI-TOF MS. Differentially 
detected proteins in HF and HDF patients’ plasma samples in fluorescence-labelled experiments, proteins a to c 
(Fig. 1), corresponding in unlabelled experiments to proteins 12, 22 and 23 (Fig. 2), respectively, and were identi-
fied as the exact same proteins, results that are shown in Table 2. Other proteins identified in plasma samples from 
HF and HDF patients are shown in Supplementary Table S1. The MALDI-TOF MS spectra and the identifications 
done with the database searches are shown in Supplementary Material. In summary, we found that HF patients 
showed higher levels of α-1-antitrypsin (protein 12), transthyretin (protein 22) and haptoglobin α1 (protein 23).
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Table 1.  Demographics, biochemistry and treatment prescriptions of the studied haemodialysis patients. Data 
expressed as mean SD. ap values between HF and HDF patients were performed by t-test; bp values by Fischer’s 
test. *p < 0.1, **p < 0.01 and ***p < 0.001. HD, haemodialysis; DM, diabetes mellitus; GN, glomerulonephritis; 
PCKD, polycystic kidney disease.
Studied haemodialysis patients pa
High-Flux Haemodialysis (HF) (n = 10) On-Line Haemodiafiltration (HDF) (n = 9) HF versus HDF
Patient demographics
Gender (M/F) 4/6 5/4 0.6563b
Age (yr) 64.00 ± 9.84 70.89 ± 15.35 0.2553
Charlson Comorbidity Index (before start HD) 6.63 ± 3.38 6.50 ± 2.39 0.9331
Cause of ESRD (no. of patients)
DM (1), GN (2), PCKD (1), nefroangiosclerosis-
ischemia (1), interstitial nephritis (2), multiple 
myeloma (1), amyloidosis (1), hyperfiltration (1)
DM (1), GN (1), PCKD (1), nefroangiosclerosis-
ischemia (1), interstitial nephritis (2), amyloidosis (1), 
bilateral nephrectomy (1), unknown (1)
Dialysis vintage (months) 36.35 ± 34.68 41.61 ± 19.38 0.6930
Weight (kg) 63.05 ± 20.32 70.89 ± 12.81 0.3351
Height (m) 1.58 ± 0.09 1.60 ± 0.09 0.5833
Body mass index (kg/m2) 24.98 ± 6.41 27.53 ± 4.05 0.3206
Systolic blood pressure (mmHg), pre-dialysis 135.00 ± 33.88 127.56 ± 11.22 0.5387
Diastolic blood pressure (mmHg), pre-dialysis 70.80 ± 15.16 65.11 ± 13.86 0.4071
Blood chemistry pre-dialysis
Leukocyte count (× 103/µl) 7.44 ± 4.47 7.19 ± 1.85 0.8772
Haemoglobin (g/dL) 10.77 ± 2.27 12.46 ± 1.17 0.0612 *
Haematocrit (%) 32.33 ± 6.37 36.97 ± 4.27 0.0831 *
Mean corpuscular volume (fL) 96.49 ± 3.54 96.27 ± 4.77 0.9084
Ferritin (ng/ml) 458.40 ± 319.52 424.10 ± 279.26 0.8072
Albumin (g/dL) 3.28 ± 0.41 3.29 ± 0.14 0.9514
Creatinine (mg/dL) 9.78 ± 3.12 10.18 ± 2.34 0.7579
Urea (mg/dL), pre-dialysis 145.80 ± 52.68 139.78 ± 32.23 0.7707
Sodium (mM/L) 139.20 ± 2.53 137.89 ± 1.27 0.1791
Potassium (mM/L) 5.36 ± 0.77 5.78 ± 0.58 0.2025
Fasting blood sugar (mg/dL) 112.80 ± 54.42 114.56 ± 42.06 0.9388
Cholesterol (mg/dL) 187.20 ± 56.87 182.44 ± 43.69 0.8419
HDL-C (mg/dL) 38.40 ± 19.63 38.89 ± 10.47 0.9477
LDL-C (mg/dL) 116.68 ± 46.80 115.07 ± 37.48 0.9354
Triglyceride (mg/dL) 163.70 ± 73.22 141.00 ± 41.73 0.4253
Uric acid (mg/dL) 8.73 ± 1.58 6.78 ± 1.16 0.0075 **
Alanine amonitransferase (U/L) 10.70 ± 3.92 13.33 ± 5.61 0.2479
Aspartate aminotransferase (U/L) 11.40 ± 3.10 13.67 ± 4.36 0.2052
ƴ-glutamyl transferase (U/L) 35.70 ± 30.85 41.89 ± 33.57 0.6806
Alkaline phosphatase (U/L) 136.27 ± 102.76 108.44 ± 43.77 0.4626
Total bilirubin (mg/dL) 0.53 ± 0.11 0.58 ± 0.14 0.3900
Calcium (mg/dL) 8.48 ± 0.64 8.37 ± 0.68 0.7138
Phosphate (mg/dL) 4.87 ± 1.99 4.23 ± 1.36 0.4325
Calcium x phsphate (mg/dL) 40.93 ± 16.45 35.31 ± 11.20 0.4019
Intact-parathyroid hormone 367.33 ± 278.09 525.18 ± 366.40 0.3019
25(OH) Vitamin D 24.00 ± 9.57 21.42 ± 9.44 0.5629
Blood chemistry post-dialysis
Urea (mg/dL), post-dialysis 41.80 ± 19.26 31.44 ± 8.50 0.1559
HD treatment prescriptions
Kt/V 1.50 ± 0.22 1.75 ± 0.30 0.0532 *
Total Kt/V 1.50 ± 0.22 1.75 ± 0.30 0.0532 *
Blood flow rate (ml/min) 318.89 ± 26.19 384.44 ± 24.04 0.0001 ***
Kt 41.49 ± 6.48 50.91 ± 5.06 0.0027 **
Gained weight (kg) 3.24 ± 0.68 2.30 ± 0.32 0.2308
Medical prescriptions
Nº of patients with EPO treatment/nº patients 10/10 3/9 0.0031b,**
rhEPO dose (U/week) in treated patients 9,200 ± 6,957 5,000 ± 1732 0.3356
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Detection of low mass proteins in plasma samples of HF and HDF patients. Interestingly, hap-
toglobin α2, transthyretin and haptoglobin α1, are proteins with a low mass that were detected in lower levels 
in HDF patients’ samples and could be cleared by the more efficient haemodiafiltration process. Therefore, we 
decided to study these proteins in unlabelled samples to characterize these differences. Individual albumin/
IgG-depleted plasma samples from each of the ten HF and nine HDF patients were analysed independently 
by SDS-PAGE and stained with Coomassie blue (Fig. 3A). Proteins 20 to 23 were quantified and after protein 
digestion identified by MALDI-TOF MS and confirmed as expected as haptoglobin α2 (proteins 20 and 21), 
transthyretin (protein 22) and haptoglobin α1 (protein 23) (Fig. 3A). Since proteins 20 and 21 were both identi-
fied as haptoglobin α2, they were quantified together and showed similar intensity values in HF and HDF patient 
samples (Fig. 3B). This result was consistent with the absence of differences found for this protein between HF 
and HDF groups in the differential protein detection experiments (Fig. 1B). The changes for haptoglobin α2, 
transthyretin and haptoglobin α1 were 1.1-, 1.7- and 1.9-fold, respectively (Fig. 3B). Differences in haptoglobin 
α1 were significant (Fig. 1B, protein c; and Fig. 3B), but after further study, this was found to be a result of an 
Figure 1.  Differential protein detection of plasma samples of HF compared with HDF patients by fluorescence 
in gel electrophoresis (DIGE). (A) Albumin- and IgG-depleted plasma samples from high-flux haemodialysis 
(HF) and on-line haemodiafiltration (HDF) patients, were labelled with Cy5 or Cy3 fluorescent dyes. After 
labelling, the HF and HDF samples were combined and analysed by sodium dodecyl sulphate–polyacrylamide 
gel electrophoresis (SDS-PAGE) and the gel was scanned to display fluorescence-labelled proteins. For 
representative purpose a gel of pooled plasma samples of HF and HDF labelled with Cys is shown; proteins 
in the HF sample were labelled with Cy5 (red) and proteins in the HDF sample labelled with Cy3 (green). 
Proteins present in both HF and HDF samples were visualised in yellow due to the merge of the red and green 
labels (HF + HDF). The numbers on the left indicate the apparent molecular mass in kDa. The combinations 
of individual paired and Cy-labelled samples of HF and HDF are shown in Figure S2. (B) Quantification of 
the fluorescent proteins detected in individual HF and HDF samples from Figure S2 for differential detection. 
Graphs show the proteins levels (fluorescence intensity, in arbitrary units, A.U.) with significant differences in 
HF compared with HDF samples. Data represented as the mean of 9 independent combinations of 9 HF and 
9 HDF patients. Error bars indicate SE; *p < 0.05, HF compared with HDF by t-test. The differentially detected 
proteins, a to c, are indicated in A by arrows with the highest labelling colour code (red, HF patients). (C) Gel 
A stained with Coomassie blue for protein staining and subsequent MALDI-TOF MS identification. Letters 
indicate the differentially detected proteins. Images of fluorescence labelling in A and stained image in C are a 
representative result and correspond to the same gel lane.
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imbalance in the allele distribution between the groups (Hp1 or Hp2), and not due to a difference in protein 
levels (see Supplementary Material). In summary, transthyretin (TTR) showed the most significant difference in 
protein levels between HF and HDF patients’ groups (Fig. 3B), finding that was consistent with the result shown 
in Fig. 1B (protein b).
LC–MS/MS analysis of plasma samples of HF and HDF patients. To assess additional proteins with 
protein abundance changes in HDF patients as compared with HF patients, we performed a quantitative pro-
teomics analysis based on LC–MS/MS. Plasma samples from nine patients per HF and HDF group (the same 
patients as in DIGE analysis) were digested with trypsin and the resulting tryptic peptides were labelled with 
isobaric tags. After LC–MS/MS analysis, the proteins identified in HF and HDF patients were subjected to sta-
tistical analysis to determine significant changes in protein abundance in HDF samples compared with the HF 
as control group (Table 3). Only those proteins identified with more than one peptide and detected across all 
18 samples were considered, which resulted in 233 proteins quantified (Supplementary Table S2). Of these, 3 
were found to be increased in HDF patients (Zq ≥ 2.0, p ≤ 0.05) and 7 decreased (Zq ≤ −2.0, p ≤ 0.05) (Table 3). 
Among the proteins found increased in HDF patient, trypsin-1, immunoglobulin heavy constant chain α-1 and 
a protein highly similar to serotransferrin were identified. The latter protein that was also found significantly 
Table 2.  Proteins differentially detected in plasma samples of HF and HDF patients identified by MALDI-
TOF MS. a Proteins identified by MALDI-TOF MS were named with letters according to differential protein 
detection in fluorescence-labelled experiments (Fig. 1), and in bwere named with the corresponding numbers 
in unlabelled and Coomassie blue-stained experiments (Fig. 2). cAccession number in UniProt database (https 
://www.unipr ot.org). dProtein identification scores > 56 were significant (p < 0.05) in the MASCOT database 
search algorithm. eMALDI LIFT-TOF/TOF MS identification mode; the m/z of the fragmented parental 








searched % Coverage Lifte (score)
a 12 Alpha-1-antit-rypsin P01009 SERPINA1 46,737 98 10/41 27 1641.83 (99)
b 22 Transthyretin P02766 TTR 13,761 64 6/65 61 2,451.20 (189)
c 23 Haptoglobin α1 P00738 HP 9,192 64 10/81 19 1708.91 (91)
Figure 2.  SDS-PAGE of plasma samples from HF and HDF patients for protein detection and MS 
identification. Gel stained with Coomassie blue shows the stained proteins in albumin/IgG-depleted plasma 
pools from HF and HDF samples. Detected proteins are indicated with numbers (bands 1–24) and were 
processed for identification by MALDI-TOF MS. Letters indicate the proteins differentially detected and shown 
in Fig. 1. The numbers on the left indicate the apparent molecular mass in kDa. The figure shows representative 
HF and HDF samples ran in the same stained gel.
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increased according to the more strict FDRq-based criterion (FDRq < 0.05, see Methods). Seven proteins were 
detected with lower levels in HDF patients –i.e., with higher levels in HF patients– which included apolipopro-
teins E and C-III and haptoglobin-related protein, the latter also significantly increased according to the more 
restrictive FDR-based criterion (FDRq < 0.05) (Table 3). The other four proteins were uncharacterized proteins 
(Table 3). Interestingly, the eighth protein with lower levels in HDF patients corresponded to transthyretin, with 
a quantification value (Zq = −1.97, Table S2 and Table 3) very closely to the limit of statistical significance (Zq 
≤ −2.0, p ≤ 0.05). Complete information of the proteins quantified in LC–MS/MS-based study is listed in Sup-
plementary Table S2.
Figure 3.  Transthyretin detection in individual HF and HDF patients’ plasma samples. (A) Individual albumin- 
and IgG-depleted plasma samples from each HF and HDF patient were analysed independently by SDS-PAGE 
and stained with Coomassie blue. Proteins haptoglobin α2 (20 and 21), transthyretin (22) and haptoglobin 
α1 (23) were identified by MALDI-TOF MS. The figure shows stained whole gels corresponding to HF and 
HDF patients. The numbers on the left indicate the apparent molecular mass in kDa. (B) Quantification of 
haptoglobin α2, transthyretin (TTR), and haptoglobin α1 (arbitrary units, A.U.). Graphs show the proteins levels 
in HF and HDF samples represented as the mean of the 10 and 9 samples, respectively. Error bars indicate SE; 
*p < 0.05, HF compared with HDF by t-test.
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Haemodiafiltration provides a greater removal of middle mass molecules (0.5–40 kDa)10 and could be doing 
a more efficient clearance of plasma in HDF patients. Thus, the identification of low-middle molecular mass 
proteins (≤ 40 kDa) in plasma samples from HF and HDF patients resulted in 115 proteins (Table S2). Of these, 
75 showed lower levels in HDF patients, including transthyretin, apolipoproteins E and C-III and haptoglobin-
related protein, whilst 40 showed higher levels, with trypsin-1 and immunoglobulin heavy constant chain α-1 
(Table 3). In summary, a total of 233 proteins were identified and quantified in plasma samples from HF and HDF 
patients in the LC–MS/MS analysis. We found that HDF patients showed higher levels of trypsin-1, immuno-
globulin heavy constant chain α-1 and a protein highly similar to serotransferrin. Whereas, HF patients showed 
higher levels of apolipoproteins E and C-III, haptoglobin-related protein and transthyretin, confirming the results 
described above for this last protein.
Transthyretin peptide quantification in patients’ plasma samples. To confirm these differences 
found in the protein levels of TTR between the patients from both groups, TTR from individual HF and HDF 
patients’ plasma samples (Fig. 3A, protein 22) was excised, processed for trypsin digestion and TTR peptides 
quantified in the MALDI-TOF MS spectra (Fig. 4A). TTR peptides from MALDI-TOF MS spectra were quan-
tified in the mass rage of the calibration experiments (TTR peptides at m/z from 833.40 to 2,451.20, Fig. 4B) 
as relative intensities (ratio TTR peptide intensity/angiotensin-II intensity, see Supplementary Material). The 
quantified levels of each TTR peptide for individual HF and HDF samples are shown in Fig. 4B. HF patients had 
a significantly increased relative intensity of TTR in five of the six TTR peptides quantified. This result confirmed 
that HF patients had an increased level of TTR.
Transthyretin levels in patients’ plasma samples. Finally, differences in TTR protein levels between 
HF and HDF patients were detected and confirmed by western blot analysis. Individual albumin/IgG-depleted 
plasma samples were analysed independently by SDS-PAGE, blotted on PVDF membrane and after the mem-
branes incubated with a specific anti-TTR antibody to TTR detection (Fig. 5). TTR signal was quantified in each 
patient and the results showed that HF patients had significantly higher levels of TTR (1.6-fold) compared with 
HDF patients (Fig. 5, box graph).
Discussion
In our study, HDF patients had higher Kt/V, as reported by a recent  study10. The Kt/V is the intradialytic urea-
reduction ratio, and it is used as a measure of haemodialysis efficacy. The increased Kt/V correlated with increased 
clearance of urea (post-dialysis urea) by the dialyzer, although, this difference was not significant.
Table 3.  Proteins with abundance changes in plasma samples of HDF compared with HF patients in LC–MS/
MS analysis. a Accession number in UniProt database (https ://www.unipr ot.org). bProtein quantification values 
(Zq) are normalized log2-ratios expressed in standard deviation units: Zq > 0 and Zq < 0 indicate increased or 
decreased, respectively, protein abundance in HDF compared with HF patients. cZq values in a colour scale; red 
and blue represent increased or decreased levels, respectively, in HDF compared with HF. Zq ≥ 2, and ≤ −2, were 
significant (p ≤ 0.05); #significant FDRq value (< 0.05).
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Interestingly, HDF patients showed significant lower uric acid levels compared with HF patients, a finding 
which has not been previously reported (Table 1). On-line haemodiafiltration does provide a greater clearing per 
unit surface area of small and middle molecules and high convection volume, and uric acid is a small (168 Da) 
and very water-soluble molecule, so this finding is coherent.
Haemoglobin and haematocrit were lower in HF patients than in HDF patients (Table 1). Moreover, the 
anaemia control in HDF patients was good and only three of the patients required rhEPO, and at low doses. 
These differences cannot be attributed to other causes of anaemia since there were no differences in the mean 
corpuscular volume nor in the ferritin levels (Table 1), and both groups were being supplemented with folic 
acid and iron. Additionally, liver function parameters were similar. Consequently, our results demonstrated that 
on-line haemodiafiltration improves anaemia control with reduced erythropoietin doses. This finding was also 
described by Maduell et al.11, who hypothesised that these differences may be due to the increased dialysis doses 
of on-line haemodiafiltration and to the greater elimination of middle-sized molecules.
Protein profiles in ESRD patients are altered by the haemodialysis process in a very notable  way6. When study-
ing and comparing the effect of these two haemodialysis techniques combining two complementary approaches 
of quantitative proteomics, we have found proteome differences which had not been described before. In the 
differential protein detection by fluorescence DIGE, α-1-antitrypsin and TTR showed significantly increased 
protein levels in HF samples compared with HDF (Fig. 1, Table 2). In the LC–MS/MS study, HDF patients showed 
higher levels of a protein highly similar to serotransferrin, trypsin-1 and immunoglobulin heavy constant chain 
α-1. In contrast, HF patients showed higher levels of apolipoproteins E and C-III, haptoglobin-related protein 
and TTR (Table 3). The α-1-antitrypsin protein (a trypsin inhibitor) was identified in LC–MS/MS study and, 
although here the change in protein abundance was in the same direction than in DIGE analysis, it showed no 
significant changes between the HF and HDF groups. The TTR identified in the LC–MS/MS analysis showed 
protein abundance changes in the same direction as those found in differential protein detection in DIGE analysis 
(Fig. 1, Table 2), supporting the results of the TTR identified in both studies. Hence, with isobaric labelling and 
LC–MS/MS analysis additional differential proteins were identified, which clearly shows that this approach is a 
powerful technique compared to differential protein detection by 1-D DIGE, although both approaches can be 
complementary to determine protein of physiological interest.
TTR result was confirmed comparing TTR levels in HF and HDF patients’ plasma samples in the stained 
gel-based approach (Fig. 3). Moreover, we found that HF patients had increased levels in 5 of the 6 TTR peptides 
by MS quantification (Fig. 4) and had increased levels of TTR detected by western blot and later quantification 
(Fig. 5). Thus, the fold change for TTR in plasma samples between HF and HDF patients was 1.6-, 1.7- and 1.6-
fold according to the results of Figs. 1, 3 and 5, respectively, all of which data that were in agreement. Herein, 
DIGE data and western blot quantification yield the exact fold change for TTR in HF samples compared with 
HDF (1.6-fold) showing the strength of both approaches.
Regarding the identification of low-middle molecular mass proteins in plasma samples in HDF patients that 
could be cleared by the more efficient haemodiafiltration  process10, the LC–MS/MS analysis found 115 proteins 
of which 75 showed lower levels in HDF, including five of the eight proteins with lower levels in HDF compared 
with HF group. The quantification of these 115 proteins by isobaric labelling in the LC–MS/MS-based study 
showed a significant correlation against their theoretical molecular mass (p < 0.0043, Pearson test), being the 
middle mass proteins more commonly decreased in HDF patients (Figure S6). This result could be confirming 
a more efficient haemodiafiltration process on middle molecular mass proteins.
Transthyretin (or prealbumin), is synthesised by the choroid plexus of the brain and by the liver and catabo-
lised in the liver and in the kidneys. TTR is known for transporting thyroid hormones and vitamin A (by forming 
the retinol transport complex with retinol-binding protein (RBP)-4) in blood and cerebrospinal fluid. Interest-
ingly, ESRD patients have increased TTR serum concentrations compared with healthy  subjects12, however, the 
role of TTR in anaemia has not been studied before.
Anaemia in ESRD patients has been attributed to inflammation, partly because a uremic milieu promotes 
an inflammatory response, which would inhibit EPO  synthesis5. Anaemia of inflammation is thought to be a 
result of iron sequestration leading to defective erythropoiesis, due to the inhibiting effect of proinflammatory 
 cytokines13. Following this, it has been described that proinflammatory cytokines increase hepcidin expression 
decreasing duodenal iron  absorption14. However, this does not explain why ESRD patients might not be able to 
use their iron stores effectively, e.g., with iron supplementation treatment, and therefore have  anaemia15.
Transferrin-bound iron is the only source of iron for erythroid precursors, required for haemoglobin synthesis 
and maturation in the bone marrow. If iron is not delivered into erythroid precursors, erythroid maturation is 
halted, leading to anaemia. A recent study has shown that aggregated TTR inhibits transferrin  endocytosis16. 
Notably, this inhibition was reversible because the removal of the aggregated TTR restored normal transferrin 
endocytic activity in  cells16. Related to this interesting finding, it is known that normal TTR can induce TTR 
 aggregates16,17.
Our results show that HDF patients have decreased TTR levels and a reduced incidence of anaemia and 
rhEPO requirements. Given that on-line haemodiafiltration provides an increased clearance of middle-sized 
molecules (0.5–40 kDa), it can increase the removal of in excess TTR –which could aggregate–, hence increas-
ing transferrin endocytosis and favouring erythropoiesis. Thus, our suggested mechanism for anaemia in ESRD 
patients is that an increased level of TTR could induce TTR aggregates, inhibiting transferrin endocytosis, this, 
in turn, decreases intracellular iron, reducing erythropoiesis and leading to anaemia.
HDF patients have significantly lower rhEPO requirements and have lower TTR levelsand increased a protein 
highly similar to serotransferrin. Serotransferrin is considered a marker of  erythropoiesis18–20 and this result 
would indicate that these patients are carrying out more erythropoiesis. These findings are of clinical relevance 
and future studies should be conducted, exploring further into the beneficial role of on-line haemodiafiltration 
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in ESRD patients. Thus, TTR could be a critical actor for anaemia in ESRD patients and could also be a novel 
biomarker for haemodialysis adequacy.
Methods
Subjects. The patients for the study were selected randomly from the list of patients that were going to attend 
their usual high-flux haemodialysis or on-line haemodiafiltration session on the same day, and were named as 
HF or HDF patients, respectively. Following the standard procedure, blood samples were drawn prior to the start 
of haemodialysis procedure for follow-up and clinical control of patients, and coded and used for this study. We 
performed a power analysis (https ://www.bioma th.info/power /ttest .htm) to determine sample size. We chose 
the significant level at 0.05 and the power set at 0.8 (80%), and the sample size obtained was 9 subjects per group. 
In this way, blood samples from ten HF and HDF patients were studied. One HDF patient revoked later the 
informed consent and removed from the study, with the HDF group having nine patients.
Data concerning the type of dialysis, their kidney disease, and their demographic status was collected from the 
haemodialysis database for these patients, preserving their anonymity and analysed blindly. Data from patients’ 
samples were independently analyzed and treatment information was blindly performed throughout the study. 
Informed consent was obtained from all subjects and the study was approved by the Research Ethical Committee 
from the Hospital Universitario Ramón y Cajal (Madrid, Spain) and according to the Declaration of Helsinki. 
Figure 4.  Mass spectra and quantification of transthyretin (TTR) peptides of HF and HDF paients by mass 
spectrometry. (A) Mass spectra of the TTR peptides from trypsin digestion obtained by MALDI-TOF MS. The 
spectra show the m/z peaks corresponding to human TTR peptides from HF (red) and HDF (blue) samples and 
the angiotensin-II peptide, added as internal standard (black). Peptide intensities in arbitrary units (A.U.); m/z 
values of  MH+ peaks of TTR peptides and angiotensin-II are indicated. (B) TTR peptides, with  MH+ peaks at 
m/z 833.40, 1,366.75, 1,394.62, 1,416.77, 1522.71 and 2,451.20 were quantified with respect to the angiotensin-II 
peptide (internal standard) as relative intensities (ratio TTR peptide intensity/angiotensin-II intensity). The 
graph shows the quantified levels of each TTR peptide for individual HF and HDF samples. Data represent 
individual values and horizontal lines represent the mean. *p < 0.05 and **p < 0.01, HF group compared with 
HDF group by t-test.
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The description of high-flux haemodialysis and on-line haemodiafiltration and the baseline characteristics of 
the studied patients are included in the Supplementary Material.
Plasma samples. Blood samples from HF and HDF patients were analysed following the standard clinical 
laboratory methods. Pre-dialysis concentrations of electrolytes, urea and creatinine, along with the haemogram, 
the lipid profile, the liver function indices and the calcium-phosphate metabolic parameters, were determined 
by routine clinical laboratory methods. Urea concentration was measured before and after treatment. Plasma 
samples were obtained and albumin and IgG removed to improve the resolution of in-gel proteomic analysis and 
were analysed blindly at the proteomic laboratory. Detailed protocol of plasma sample processing is included in 
Supplementary Material.
Gel electrophoresis and fluorescence labelling. Plasma samples from HF and HDF patients (15 μg of 
protein) were separated and analysed by denaturating sodium dodecyl sulphate–polyacrylamide gel electropho-
resis (SDS-PAGE) of 12% acrylamide (3% cross-linking). Low molecular weight calibration kit (GE Healthcare) 
for SDS-PAGE was used as molecular mass standards.
In DIGE experiments, plasma samples from HF and HDF patients (5 μg of protein) were labelled with 
Cy3 or Cy5 fluorescent dyes (GE Healthcare) according to the standard protocol for DIGE assay, as previously 
 described21. Labelling was performed in samples from HF and HDF patients (n = 9 per group) in a paired 
combination. A sample of HF (patient 1) was randomly discarded and the labelling was alternated between 
Cy3 and Cy5 in each group. After fluorescence labelling, HF and HDF samples were combined and analysed by 
SDS-PAGE as described above. In the Cy-labelled experiments for subsequent MALDI-TOF MS identification 
pools (n = 5) of both HF and HDF patients’ plasma samples were combined. A detailed protocol is included in 
the Supplementary Material.
Figure 5.  Transthyretin (TTR) detection by western blot in HF and HDF plasma samples. Individual albumin- 
and IgG-depleted plasma samples of each HF and HDF patient were analysed independently by western blotting 
with anti-TTR antibody (images). In the images, arrows show the TTR protein detected, and the numbers on 
the left indicate the apparent molecular mass from standards. The box graph show the quantification of the TTR 
levels (arbitrary units, A.U.) detected in HF and HDF samples represented as the mean of the 10 and 9 samples, 
respectively, (thick line) ± 25% and 75% percentile (box) and the minimum and maximum TTR level (whiskers). 
*p < 0.05, HF compared with HDF by t-test. Images show whole blots. Blotted proteins were staining with 
Fast Green as loading control of the analyzed samples, and used for normalization of detected TTR levels (see 
Figure S5 in the Supplementary Material).
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Coomassie brilliant blue (R-250, BioRad) was used to stain the proteins in gels, that after were washed-out 
with 20% ethanol/7% acetic acid (vol/vol). Finally, gels were preserved in 10% ethanol until scanning and protein 
quantification, or extraction for subsequent identification by MS.
In‑gel protein digestion and protein identification by mass spectrometry. Gel bands were 
excised manually from the Coomassie blue-stained gels for tryptic digestion with modified porcine trypsin 
(Promega). The digestion protocol was according to Shevchenko et  al., with minor variations, as previously 
 described21,22. After digestion, peptide mass fingerprinting (PMF) was analyzed by MALDI-TOF MS (Autoflex 
III, Bruker-Daltonics) for protein identification, as previously  described21. Additionally, when available and for 
confirmation of protein identity, peptide fragmentation was performed by MS in tandem MALDI LIFT-TOF/
TOF23. Detailed protocol is included in the Supplementary Material. Additionally, results of protein searches and 
spectra in the case of MALDI-TOF MS- and LIFT-TOF/TOF-based protein identifications are included in the 
Supplementary Material Sects. 16 and 17, respectively.
Protein quantification. The fluorescence-labelled proteins in DIGE experiments were detected scanning 
the gels using a Typhoon 9,200 imager (GE Healthcare). Differential protein detection between HF and HDF 
samples was quantified in the scanned images using the Quantity One software package (Bio-Rad). Proteins 
stained with Coomassie blue were scanned and quantified using an image analyser equipped with the Quantity 
One software. The data obtained were processed using Microsoft Excel spreadsheet and Prism statistical package 
(GraphPad Software).
LC–MS/MS analysis. Plasma samples (6  μl, without albumin/IgG depletion) were boiled for 5  min at 
100 °C in the presence of 25 mM Tris–HCl pH 6.8, 1% SDS and 50 mM DTT, diluted with denaturing buffer 
(8  M urea in 100  mM Tris–HCl pH 8.5) and after washing, samples were digested overnight at 37  °C with 
sequencing grade trypsin (Promega). The resulting tryptic peptides from each sample were recovered and their 
concentration was determined using a Direct Detect IR spectrometer (Millipore). Equal amounts of each pep-
tide sample were labelled with isobaric 10-plex tandem mass tags (TMT) (Thermo Fisher Scientific) according 
to the manufacturer’s instructions and mixed together. An internal control was prepared by pooling the nine HF 
samples (control group) and was used as a reference to express relative quantification values. A detailed protocol 
is included in the Supplementary Material.
For peptide identification, labelled tryptic peptide samples were applied to an EASY-nLC 1,000 nano-flow 
HPLC system (Thermo Fisher Scientific) coupled on-line with an orbitrap Fusion mass spectrometer (Thermo 
Fisher Scientific). C18-based reverse phase separation was used with a 2-cm trap column and a 50-cm analytical 
column (EASY-Spray, Thermo Fisher Scientific). Mass spectra were acquired and LC–MS/MS data were analyzed 
with Proteome Discoverer (version 2.1, Thermo Fisher Scientific) using SEQUEST-HT (Thermo Fisher Scien-
tific). Peptide identification from MS/MS data was performed using the probability ratio  method24. Peptides 
were assigned only to the best protein proposed by the Proteome Discoverer algorithm. A detailed protocol is 
included in the Supplementary Material.
Quantification at the peptide and protein levels in LC–MS/MS analysis. The quantitative infor-
mation extracted from the MS/MS spectra by Proteome Discoverer was integrated from the spectrum level to 
the peptide level and then to the protein level on the basis of the WSPP  model25 and the systems biology triangle 
 algorithm26 using the SanXoT software  package27. A log2-ratio of every scan was calculated using the TMT 
reporter ion intensities coming from samples and the reference. Thus, the quantification of each peptide and 
protein was calculated as the weighted average of its scans or peptides, respectively, and expressed in standard 
deviation units as Zq value. A threshold of Zq ≥ 2, or ≤ −2, was considered significant (p ≤ 0.05)25. Additional 
information is included in the Supplementary Material.
Quantification of TTR peptides by mass spectrometry. After in-gel protein digestion, angiotensin-II 
peptide (4 fmol) was added to collected tryptic peptides. Peptides obtained from the digestion and the angio-
tensin-II peptide were analysed by MALDI-TOF MS, and peptide intensities in the MS spectra were quantified 
with respect to the angiotensin-II peptide intensity as a ratio of the relative intensities peptide/angiotensin-II. 
Calibration experiments carried out to test the accuracy of this quantification are included in the Supplementary 
Material.
Western blot analysis. Albumin- and IgG-depleted plasma samples from HF and HDF patients (5 μg of 
protein) were analysed by SDS-PAGE as describe above, and transferred onto PVDF membranes (GE Health-
care). The membranes were incubated overnight at 4 °C with rabbit polyclonal anti-TTR antibody (ab78548, 
Abcam), washed, then incubated for 1 h with peroxidase-conjugated anti-rabbit IgG (GE Healthcare), and devel-
oped with Clarity reagent (Bio-Rad). TTR protein was detected scanning the membranes using a ChemiDoc 
MP imager (Bio-Rad) and quantified using the Quantity One software (Bio-Rad). In all experiments, blotted 
proteins were staining with Fast Green (Bio-Rad) in the PVDF membranes as loading control of the samples.
Data collection and statistical analyses. The patients’ data from the haemodialysis database was col-
lected and analysed blindly. To compare and determine differences between the groups, statistical analysis was 
performed using Microsoft Excel spreadsheets and the Prism statistical package (GraphPad Software). Data 
are presented in arbitrary units (A.U.) unless specified, and expressed as mean ± SD for the nineteen patients. 
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Comparisons were done by the Student’s t test for continuous variables and Fisher’s test for categorical variables. 
Pearson test was used to calculate linear correlations.
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